Enfusion Net Worth
Enfusion Net Worth Breakdown | ENFN |
Enfusion Net Worth Analysis
Enfusion's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Enfusion's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Enfusion's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Enfusion's net worth analysis. One common approach is to calculate Enfusion's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Enfusion's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Enfusion's net worth. This approach calculates the present value of Enfusion's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Enfusion's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Enfusion's net worth. This involves comparing Enfusion's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Enfusion's net worth relative to its peers.
Enterprise Value |
|
To determine if Enfusion is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Enfusion's net worth research are outlined below:
| Enfusion is unlikely to experience financial distress in the next 2 years | |
| Enfusion has a very strong financial position based on the latest SEC filings | |
| Over 97.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Enfusion Third Quarter 2024 Earnings Misses Expectations |
Enfusion uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Enfusion. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Enfusion's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 5th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 5th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Enfusion's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Enfusion is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Enfusion backward and forwards among themselves. Enfusion's institutional investor refers to the entity that pools money to purchase Enfusion's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | T. Rowe Price Investment Management,inc. | 2024-09-30 | 1.3 M | Next Century Growth Investors Llc | 2024-06-30 | 1.1 M | Geode Capital Management, Llc | 2024-06-30 | 959 K | State Street Corp | 2024-06-30 | 931.2 K | Wellington Management Company Llp | 2024-06-30 | 915.3 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 688.5 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 580.6 K | Bank Of America Corp | 2024-06-30 | 579.7 K | Impax Asset Management Group Plc | 2024-06-30 | 540 K | Iconiq Capital, Llc | 2024-06-30 | 14 M | Brown Capital Management, Llc | 2024-09-30 | 7.2 M |
Follow Enfusion's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 933.34 M.Market Cap |
|
Project Enfusion's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.06 | 0.06 | |
| Return On Capital Employed | 0.13 | 0.14 | |
| Return On Assets | 0.06 | 0.06 | |
| Return On Equity | 0.11 | 0.12 |
When accessing Enfusion's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Enfusion's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Enfusion's profitability and make more informed investment decisions.
Evaluate Enfusion's management efficiency
Enfusion has return on total asset (ROA) of 0.0592 % which means that it generated a profit of $0.0592 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0548 %, meaning that it created $0.0548 on every $100 dollars invested by stockholders. Enfusion's management efficiency ratios could be used to measure how well Enfusion manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of November 2024, Return On Tangible Assets is likely to grow to 0.06. Also, Return On Capital Employed is likely to grow to 0.14. At this time, Enfusion's Net Tangible Assets are very stable compared to the past year. As of the 22nd of November 2024, Other Current Assets is likely to grow to about 7 M, while Total Assets are likely to drop about 88.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.88 | 0.92 | |
| Tangible Book Value Per Share | 0.88 | 0.92 | |
| Enterprise Value Over EBITDA | 69.92 | 78.42 | |
| Price Book Value Ratio | 15.94 | 16.74 | |
| Enterprise Value Multiple | 69.92 | 78.42 | |
| Price Fair Value | 15.94 | 16.74 | |
| Enterprise Value | 960.7 M | 1.9 B |
The strategic decisions made by Enfusion management significantly impact its financial stability and market performance. Evaluating these factors helps determine whether the stock is a worthwhile investment.
Enterprise Value Revenue 4.6432 | Revenue 195.2 M | Quarterly Revenue Growth 0.154 | Revenue Per Share 2.155 | Return On Equity 0.0548 |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Enfusion insiders, such as employees or executives, is commonly permitted as long as it does not rely on Enfusion's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Enfusion insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Enfusion Corporate Filings
8K | 4th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 29th of October 2024 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 24th of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 26th of April 2024 Other Reports | ViewVerify |
Enfusion Earnings per Share Projection vs Actual
Enfusion Corporate Management
| Stephen Dorton | Chief Officer | Profile | |
| Michael Berry | Chief Officer | Profile | |
| Lorelei Skillman | Chief Officer | Profile | |
| Stephen Malherbe | Managing Partner | Profile | |
| Oleg Movchan | Interim Director | Profile | |
| Matthew Campobasso | General Secretary | Profile | |
| Bronwen Bastone | Chief Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enfusion. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. To learn how to invest in Enfusion Stock, please use our How to Invest in Enfusion guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Application Software space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enfusion. If investors know Enfusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enfusion listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.27) | Earnings Share 0.04 | Revenue Per Share 2.155 | Quarterly Revenue Growth 0.154 | Return On Assets 0.0592 |
The market value of Enfusion is measured differently than its book value, which is the value of Enfusion that is recorded on the company's balance sheet. Investors also form their own opinion of Enfusion's value that differs from its market value or its book value, called intrinsic value, which is Enfusion's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enfusion's market value can be influenced by many factors that don't directly affect Enfusion's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enfusion's value and its price as these two are different measures arrived at by different means. Investors typically determine if Enfusion is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enfusion's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.